Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada : Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada
In order to assess the mother-to-infant and potential vertical transmission of SARS-CoV-2 infection in pregnant women, maternal and neonatal biological samples will be prospectively collected from women with confirmed or suspected COVID-19 at participating hospitals across Ontario. Samples will be tested for the SARS-CoV-2 serology and viral load.Outcomes for the study objective will be ascertained through the collection and testing of biological samples from the mother and/or infant. Specifically the investigators will:Assess maternal nasopharyngeal or oropharyngeal swab, vaginal mucosa, ano-rectal swab, amniotic fluid, placenta (including subamniotic swab), breastmilk, cord blood and neonatal nasopharyngeal swab for RNA particles of coronavirus, by ddPCR.Assess maternal serum for anti-coronavirus antibodies, by immunoassay.Examine the impact of coronavirus on the neonate with respect to serology and viral load, in addition to placenta pathology findings and ddPCR.Assess vertical transmission and the effect of coronavirus through placental pathology examination using placental pathology synoptic report..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
ClinicalTrials.gov - (2023) vom: 13. Apr. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: June 4, 2021, Last downloaded: ClinicalTrials.gov processed this data on April 19, 2023, Last updated: April 19, 2023 |
---|
Study ID: |
NCT04913948 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG007682638 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG007682638 | ||
003 | DE-627 | ||
005 | 20230425195225.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210610s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG007682638 | ||
035 | |a (UBBS_Klinische_Studien)NCT04913948 | ||
035 | |a (UBBS_Klinische_Studien)CTO 2168 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada |b Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: June 4, 2021, Last downloaded: ClinicalTrials.gov processed this data on April 19, 2023, Last updated: April 19, 2023 | ||
520 | |a In order to assess the mother-to-infant and potential vertical transmission of SARS-CoV-2 infection in pregnant women, maternal and neonatal biological samples will be prospectively collected from women with confirmed or suspected COVID-19 at participating hospitals across Ontario. Samples will be tested for the SARS-CoV-2 serology and viral load.Outcomes for the study objective will be ascertained through the collection and testing of biological samples from the mother and/or infant. Specifically the investigators will:Assess maternal nasopharyngeal or oropharyngeal swab, vaginal mucosa, ano-rectal swab, amniotic fluid, placenta (including subamniotic swab), breastmilk, cord blood and neonatal nasopharyngeal swab for RNA particles of coronavirus, by ddPCR.Assess maternal serum for anti-coronavirus antibodies, by immunoassay.Examine the impact of coronavirus on the neonate with respect to serology and viral load, in addition to placenta pathology findings and ddPCR.Assess vertical transmission and the effect of coronavirus through placental pathology examination using placental pathology synoptic report. | ||
650 | 2 | |a Infections | |
650 | 2 | |a Communicable Diseases | |
650 | 2 | |a COVID-19 | |
650 | 2 | |a Coronavirus Infections | |
650 | 4 | |a Study Type: Observational | |
650 | 4 | |a Recruitment Status: Completed | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 13. Apr. |
773 | 1 | 8 | |g year:2023 |g day:13 |g month:04 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04913948 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2023 |b 13 |c 04 |